Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)
NCT03065621
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer Female
Interventions
DRUG:
Palbociclib
Sponsor
Jules Bordet Institute